GENinCode PLC Notice of Results (4285K)
September 02 2021 - 2:00AM
UK Regulatory
TIDMGENI
RNS Number : 4285K
GENinCode PLC
02 September 2021
2 September 2021
GENinCode Plc
("GENinCode" or the "Company")
Notice of results
Analyst briefing and investor presentation
GENinCode Plc (AIM: GENI), the cardiovascular disease company
focused on predictive genetics for the prevention of cardiovascular
disease, announces that its interim results for the six months
ended 30 June 2021 will be released on Thursday, 16 September
2021.
Analyst briefing
A briefing open to analysts will take place remotely via video
conference call on Thursday, 16 September at 11.30 a.m. (BST). If
you would like to register for this call, please contact Walbrook
PR at GENinCode@walbrookpr.com .
Investor presentation
Chief Executive Officer, Matthew Walls, and Chief Financial
Officer, Paul Foulger, will also provide a live presentation
relating to GENinCode plc's interim results via the Investor Meet
Company platform on 16 September 2021 at 16:00 p.m. (BST).
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 09:00 a.m. (BST) the day
before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet GENinCode plc via:
https://www.investormeetcompany.com/genincode-plc/register-investor
Investors who already follow GENinCode plc on the Investor Meet
Company platform will automatically be invited.
Contacts:
GENinCode plc www.genincode.com
Matthew Walls, CEO Via Walbrook PR
Paul Foulger, CFO
Stifel Nicolaus Europe Limited (Nomad and Tel: +44 (0)20 7710 7600
Joint Broker)
Alex Price / Ben Maddison / Richard
Short
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Tel: 020 7933 8780 or genincode @walbrookpr.com
Anna Dunphy / Paul McManus / Louis
Ashe-Jepson
About GENinCode plc
GENinCode plc (AIM: GENI) is engaged in the risk assessment,
prediction and prevention of cardiovascular disease ("CVD"). CVD is
the leading cause of death worldwide accounting for approximately
18 million deaths annually. The Company's products and technology
have been developed with the aim of predicting the onset of CVD and
providing a personalised treatment pathway for patient management.
Its products have been the subject of clinical studies on over
75,000 patients to assess and predict the onset of CVD.
The Company was incorporated in September 2018 to acquire the
assets, intellectual property and know-how of the Ferrer inCode and
Gendiag.exe businesses, which were then part of Grupo Ferrer
Internacional S.A., a large Spanish multinational private
pharmaceutical and healthcare company. The technology and products
acquired included Cardio inCode(R), Lipid inCode(R), Thrombo
inCode(R) and Sudd inCode(R). The Directors believe that
approximately EUR50 million has been invested in the research and
development of these products since 2007. The Company has begun to
commercialise these products in Europe and is now targeting the UK
and US.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORLBMTTMTAMBTB
(END) Dow Jones Newswires
September 02, 2021 02:00 ET (06:00 GMT)
Genincode (LSE:GENI)
Historical Stock Chart
From Apr 2024 to May 2024
Genincode (LSE:GENI)
Historical Stock Chart
From May 2023 to May 2024